Double-conditioning regimen consisting of high-dose thiotepa and melphalan with autologous stem cell rescue for high-risk pediatric solid tumors: A second report.
Keiko OkadaKai YamasakiChika NitaniHiroyuki FujisakiYuko OsugiJunichi HaraPublished in: Pediatric blood & cancer (2019)
Our double-conditioning regimen was very well tolerated and demonstrated antitumor activity. We are moving forward with multi-institutional trials now.